Drawray

Drawray, officially known as Shenzhen Drawray Biological Technology Co., Ltd., is a biotechnology company based in Shenzhen, China. Established in May 2019, it operates as a wholly-owned subsidiary of YHLO, which has been publicly listed since 2008. Drawray specializes in the research, development, production, sales, and service of in vitro diagnostic (IVD) products, particularly in point-of-care testing (POCT) technologies. The company is certified under ISO 13485 and ISO 9001, ensuring high standards in medical device manufacturing and quality assurance. Drawray's technological capabilities encompass five major IVD platforms: Chemiluminescence Immunoassay (CLIA), Fluorescence Immunoassay (FIA), Microfluidics, Rapid Test, and Polymerase Chain Reaction (PCR). Its product portfolio addresses various clinical diagnostic areas, including cardiac markers, thyroid function, and respiratory viruses, among others. With over 40 patents and more than 90 CE certifications, Drawray is committed to innovation and compliance with international health standards. The company exports its products to markets such as India, the Philippines, and Ecuador, serving key buyers in the pharmaceutical and diagnostic sectors.

• Employees 15
• Founded 2019